The expression and clinical significance of microRNAs in colorectal cancer detecting
- 393 Downloads
MicroRNAs (miRNAs) are small non-coding RNAs which regulate gene expressions post-transcriptionally. Nowadays, various miRNAs have been found to be sensitive and specific biomarkers for the early diagnosis of colorectal cancer (CRC); however, there are different, even conflicting results in different publications concerning the diagnostic accuracy of miRNA. Therefore, we aim to conduct a meta-analysis of the relevant publications to comprehensively evaluate the diagnostic value of miRNAs in CRC detection. Several public databases such as PubMed, Embase, and Google Scholar were retrieved up to July 13, 2014. Sensitivity was applied to plot the summary receiver operator characteristic (SROC) curve against specificity. The area under the SROC curve (AUC) was calculated to assess the classified effects. STATA 12.0 software was used to perform all statistic analyses. A total of 29 articles, including 80 studies, were involved in our meta-analysis, 55 of which focus on single-miRNA assays and the other 25 on multiple-miRNA assays. Our results suggested that multiple-miRNA assays show a better diagnostic accuracy compared with single-miRNA assays. In addition, blood-based miRNA assays were more accurate than feces-based miRNA assays in CRC diagnosis. Our results also showed that miRNA diagnosis appear to be more accurate in Asians than in Caucasians. However, further researches are needed to validate our results and the feasibility of miRNAs as biomarkers in routine clinical diagnosis of CRC.
KeywordsMicroRNA Plasma Serum Feces Colorectal cancer Diagnosis Meta-analysis
This work was supported in part by the grant from National Natural Science Foundation of China (Grant # 81272251), a grant for the Innovative Team of Science and Technology, Henan Province, China.
Conflicts of interest
- 5.Wu XD, Song YC, Cao PL, Zhang H, Guo Q, Yan R, et al. Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer. Med Oncol. 2014;31:1–6.Google Scholar
- 15.Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25:1674–80. doi: 10.1111/j.1440-1746.2010.06417.x.CrossRefPubMedGoogle Scholar
- 19.Feng L, Pang Z, Sha S, Wu B, Xu F, Yin SP. The value of diagnosis and prognosis prediction of serum miR-29a and miR-92a for colorectal cancer. Chin J Clin Oncol Rehabil. 2013:1313–1315.Google Scholar
- 24.Sheinerman KS, Tsivinsky VG, Umansky SR. Analysis of organ-enriched microRNAs in plasma as an approach to development of universal screening test: feasibility study. J Transl Med. 2013; 11.Google Scholar
- 27.Yong FL, Law CW, Wang CW. Potentiality of a triple microRNA classifier: MiR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer. 2013; 13.Google Scholar
- 34.Koga Y, Yasunaga M, Takahashi A, Kuroda J, Matsumura Y. Fecal RNA test using microRNA expressions of exfoliated colonocytes for colorectal cancer screening. Cancer Res. 2011; 71.Google Scholar
- 41.Schou JV, Rossi S, Jensen BV, Nielsen DL, Pfeiffer P, Hogdall E, et al. miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. PLoS ONE. 2014;9:e99886. doi: 10.1371/journal.pone.0099886.CrossRefPubMedPubMedCentralGoogle Scholar